CD38-BINDING FUSION PROTEIN COMBINATION THERAPY
Provided herein are methods of treating cancer (e.g., CD38-expressing cancer such as multiple myeloma) using a CD38-binding fusion protein comprising an anti-CD38 antibody fused to one or more attenuated interferon alpha-2b protein in combination an additional anti- CD38 antibody (e.g., daratumumab)...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GUPTA, Neeraj WILSON, David LABOTKA, Richard PAROT, Xavier WANG, Shining COLLINS, Sabrina SAMPSON, Jim THESILLAT-VERSMEE, Laura SURYANARAYAN, Kaveri POGUE, Sarah LI, Shuang |
| description | Provided herein are methods of treating cancer (e.g., CD38-expressing cancer such as multiple myeloma) using a CD38-binding fusion protein comprising an anti-CD38 antibody fused to one or more attenuated interferon alpha-2b protein in combination an additional anti- CD38 antibody (e.g., daratumumab), and optionally additional agents (e.g., immunomodulatory drugs such as lenalidomide or pomalidomide, or proteasome inhibitors such as bortezomib or carfilzomib), for treating the cancer. In some embodiments, the cancer is multiple myeloma.
L'invention concerne des méthodes de traitement du cancer (p. ex., un cancer exprimant CD38 tel qu'un myélome multiple) à l'aide d'une protéine de fusion se liant à CD38 comprenant un anticorps anti-CD38 fusionné à une ou plusieurs protéines d'interféron alpha-2b atténuées en combinaison avec un anticorps anti-CD38 supplémentaire (p. ex., du daratumumab), et éventuellement des agents supplémentaires (p. ex., des médicaments immunomodulateurs tels que le lénalidomide ou le pomalidomide, ou des inhibiteurs de protéasome tels que le bortézomib ou le carfilzomib), pour traiter le cancer. Dans certains modes de réalisation, le cancer est un myélome multiple. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024073716A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024073716A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024073716A23</originalsourceid><addsrcrecordid>eNrjZNB3djG20HXy9HPx9HNXcAsN9vT3UwgI8g9x9fRTcPb3Bco4hoDEQjxcgxwDInkYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkYmBubG5oZmjkTFxqgCUJibn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CD38-BINDING FUSION PROTEIN COMBINATION THERAPY</title><source>esp@cenet</source><creator>GUPTA, Neeraj ; WILSON, David ; LABOTKA, Richard ; PAROT, Xavier ; WANG, Shining ; COLLINS, Sabrina ; SAMPSON, Jim ; THESILLAT-VERSMEE, Laura ; SURYANARAYAN, Kaveri ; POGUE, Sarah ; LI, Shuang</creator><creatorcontrib>GUPTA, Neeraj ; WILSON, David ; LABOTKA, Richard ; PAROT, Xavier ; WANG, Shining ; COLLINS, Sabrina ; SAMPSON, Jim ; THESILLAT-VERSMEE, Laura ; SURYANARAYAN, Kaveri ; POGUE, Sarah ; LI, Shuang</creatorcontrib><description>Provided herein are methods of treating cancer (e.g., CD38-expressing cancer such as multiple myeloma) using a CD38-binding fusion protein comprising an anti-CD38 antibody fused to one or more attenuated interferon alpha-2b protein in combination an additional anti- CD38 antibody (e.g., daratumumab), and optionally additional agents (e.g., immunomodulatory drugs such as lenalidomide or pomalidomide, or proteasome inhibitors such as bortezomib or carfilzomib), for treating the cancer. In some embodiments, the cancer is multiple myeloma.
L'invention concerne des méthodes de traitement du cancer (p. ex., un cancer exprimant CD38 tel qu'un myélome multiple) à l'aide d'une protéine de fusion se liant à CD38 comprenant un anticorps anti-CD38 fusionné à une ou plusieurs protéines d'interféron alpha-2b atténuées en combinaison avec un anticorps anti-CD38 supplémentaire (p. ex., du daratumumab), et éventuellement des agents supplémentaires (p. ex., des médicaments immunomodulateurs tels que le lénalidomide ou le pomalidomide, ou des inhibiteurs de protéasome tels que le bortézomib ou le carfilzomib), pour traiter le cancer. Dans certains modes de réalisation, le cancer est un myélome multiple.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240404&DB=EPODOC&CC=WO&NR=2024073716A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240404&DB=EPODOC&CC=WO&NR=2024073716A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GUPTA, Neeraj</creatorcontrib><creatorcontrib>WILSON, David</creatorcontrib><creatorcontrib>LABOTKA, Richard</creatorcontrib><creatorcontrib>PAROT, Xavier</creatorcontrib><creatorcontrib>WANG, Shining</creatorcontrib><creatorcontrib>COLLINS, Sabrina</creatorcontrib><creatorcontrib>SAMPSON, Jim</creatorcontrib><creatorcontrib>THESILLAT-VERSMEE, Laura</creatorcontrib><creatorcontrib>SURYANARAYAN, Kaveri</creatorcontrib><creatorcontrib>POGUE, Sarah</creatorcontrib><creatorcontrib>LI, Shuang</creatorcontrib><title>CD38-BINDING FUSION PROTEIN COMBINATION THERAPY</title><description>Provided herein are methods of treating cancer (e.g., CD38-expressing cancer such as multiple myeloma) using a CD38-binding fusion protein comprising an anti-CD38 antibody fused to one or more attenuated interferon alpha-2b protein in combination an additional anti- CD38 antibody (e.g., daratumumab), and optionally additional agents (e.g., immunomodulatory drugs such as lenalidomide or pomalidomide, or proteasome inhibitors such as bortezomib or carfilzomib), for treating the cancer. In some embodiments, the cancer is multiple myeloma.
L'invention concerne des méthodes de traitement du cancer (p. ex., un cancer exprimant CD38 tel qu'un myélome multiple) à l'aide d'une protéine de fusion se liant à CD38 comprenant un anticorps anti-CD38 fusionné à une ou plusieurs protéines d'interféron alpha-2b atténuées en combinaison avec un anticorps anti-CD38 supplémentaire (p. ex., du daratumumab), et éventuellement des agents supplémentaires (p. ex., des médicaments immunomodulateurs tels que le lénalidomide ou le pomalidomide, ou des inhibiteurs de protéasome tels que le bortézomib ou le carfilzomib), pour traiter le cancer. Dans certains modes de réalisation, le cancer est un myélome multiple.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNB3djG20HXy9HPx9HNXcAsN9vT3UwgI8g9x9fRTcPb3Bco4hoDEQjxcgxwDInkYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkYmBubG5oZmjkTFxqgCUJibn</recordid><startdate>20240404</startdate><enddate>20240404</enddate><creator>GUPTA, Neeraj</creator><creator>WILSON, David</creator><creator>LABOTKA, Richard</creator><creator>PAROT, Xavier</creator><creator>WANG, Shining</creator><creator>COLLINS, Sabrina</creator><creator>SAMPSON, Jim</creator><creator>THESILLAT-VERSMEE, Laura</creator><creator>SURYANARAYAN, Kaveri</creator><creator>POGUE, Sarah</creator><creator>LI, Shuang</creator><scope>EVB</scope></search><sort><creationdate>20240404</creationdate><title>CD38-BINDING FUSION PROTEIN COMBINATION THERAPY</title><author>GUPTA, Neeraj ; WILSON, David ; LABOTKA, Richard ; PAROT, Xavier ; WANG, Shining ; COLLINS, Sabrina ; SAMPSON, Jim ; THESILLAT-VERSMEE, Laura ; SURYANARAYAN, Kaveri ; POGUE, Sarah ; LI, Shuang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024073716A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>GUPTA, Neeraj</creatorcontrib><creatorcontrib>WILSON, David</creatorcontrib><creatorcontrib>LABOTKA, Richard</creatorcontrib><creatorcontrib>PAROT, Xavier</creatorcontrib><creatorcontrib>WANG, Shining</creatorcontrib><creatorcontrib>COLLINS, Sabrina</creatorcontrib><creatorcontrib>SAMPSON, Jim</creatorcontrib><creatorcontrib>THESILLAT-VERSMEE, Laura</creatorcontrib><creatorcontrib>SURYANARAYAN, Kaveri</creatorcontrib><creatorcontrib>POGUE, Sarah</creatorcontrib><creatorcontrib>LI, Shuang</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GUPTA, Neeraj</au><au>WILSON, David</au><au>LABOTKA, Richard</au><au>PAROT, Xavier</au><au>WANG, Shining</au><au>COLLINS, Sabrina</au><au>SAMPSON, Jim</au><au>THESILLAT-VERSMEE, Laura</au><au>SURYANARAYAN, Kaveri</au><au>POGUE, Sarah</au><au>LI, Shuang</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CD38-BINDING FUSION PROTEIN COMBINATION THERAPY</title><date>2024-04-04</date><risdate>2024</risdate><abstract>Provided herein are methods of treating cancer (e.g., CD38-expressing cancer such as multiple myeloma) using a CD38-binding fusion protein comprising an anti-CD38 antibody fused to one or more attenuated interferon alpha-2b protein in combination an additional anti- CD38 antibody (e.g., daratumumab), and optionally additional agents (e.g., immunomodulatory drugs such as lenalidomide or pomalidomide, or proteasome inhibitors such as bortezomib or carfilzomib), for treating the cancer. In some embodiments, the cancer is multiple myeloma.
L'invention concerne des méthodes de traitement du cancer (p. ex., un cancer exprimant CD38 tel qu'un myélome multiple) à l'aide d'une protéine de fusion se liant à CD38 comprenant un anticorps anti-CD38 fusionné à une ou plusieurs protéines d'interféron alpha-2b atténuées en combinaison avec un anticorps anti-CD38 supplémentaire (p. ex., du daratumumab), et éventuellement des agents supplémentaires (p. ex., des médicaments immunomodulateurs tels que le lénalidomide ou le pomalidomide, ou des inhibiteurs de protéasome tels que le bortézomib ou le carfilzomib), pour traiter le cancer. Dans certains modes de réalisation, le cancer est un myélome multiple.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2024073716A2 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | CD38-BINDING FUSION PROTEIN COMBINATION THERAPY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T00%3A51%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GUPTA,%20Neeraj&rft.date=2024-04-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024073716A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |